Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
for Major Depressive Disorder
Drug: NBI-1065845
Sites in Houston, Dallas +40 more locations
Sponsor: Neurocrine Biosciences
Sex: All·Age: 18+
Code: NCT06966401·Phase 3·Recruiting·Listed May 2025